DNA Shield: a service for sovereign data protection
DNA Shield is a managed service for sovereign data protection. It is designed to hold small, irreplaceable data offline, in-jurisdiction, and separated from the systems it protects.
- Every data protection strategy shares one weakness
The copies you would rely on to recover live inside the systems they are meant to protect: same network, same identity, same vendor, same jurisdiction. When those systems fail, or are quietly changed, your way back fails with them.
The job is not storing data.
The job is preserving digital trust. DNA Shield is designed so that the critical assets that protect, prove, and restore everything else remain independent, recoverable, and verifiable despite cyber attack, organizational change, infrastructure replacement, and regulatory scrutiny.
How it works
Selection and encryption
You identify the key material or record in scope, and encrypt before it leaves your environment.
DNA encoding under managed custody
The encrypted package is encoded into synthetic DNA by Biomemory and held offline, in-jurisdiction, and separate from the systems it protects.
Authorized recovery
You initiate the recovery through the DNA Shield Portal, the Biomemory service is designed to restore the information only through an authorized secure process.
Use case preview
Key custody continuity
An offline share and the records to keep your key recovery scheme working through custodian and vendor change.
Crown jewel industrial IP
An offline, in-jurisdiction copy of the industrial knowledge you cannot afford to lose.
Regulated integrity
A tamper-evident package proving your critical records are exactly what was approved.
Sovereign memory
Preserving records that must outlast the institutions and systems that created them.
Answers, not deflections
DNA Data Storage translates binary digital content into synthetic DNA strands. Binary data is converted into a molecular code, corresponding DNA strands are then synthesized, physically stored into a container, and later read, using available DNA-reading technologies. Biomemory industrializes this process into rackable storage servers designed for data center environments.
As data volumes scale, traditional architectures face structural physical, economic, and environmental limits. DNA introduces a new storage tier designed for long-term scalability. DNA has been selected as the molecule of choice for cold storage applications, for many combined reasons: very stable molecule, especially in its double-helix form; broad knowledge base and availability of massive characterization data; strong global trust in stability, reliability and longevity, in line with cold storage IT requirements; availability of DNA reading commercial equipment, currently and as long as human DNA shall be read; ability to replicate DNA with a very low error rate, including using living organisms (e.g. bacterias) for low-cost high-volume production.
DNA is inherently stable over extremely long periods. Milennia can be reached under very cold and hermetic special conditions. However, for IT-related applications, a retention and readability assurance of 50, 100 or 150 years is good enough. Biomemory is aligning with these market requirements and the enterprise-grade resilience levels, to offer the best cost & data accessibility trade-off. Along the specified life-time, DNA is stable and does not need to be refreshed or remastered, unlike other magnetic or electronics data storage media.
Yes. Biomemory uses fully synthetic, biosecure DNA blocks designed to prevent biological interaction, and compliant with the most stringent biosecurity regulation or recommendation. Our DNA, by design, cannot express proteins or interact with living systems. Biosafety is embedded by design at the molecular level, and validated by independent third party compliance testing
DNA enables structurally lower long-term total cost of ownership. Ultra-low energy consumption at rest, elimination of frequent hardware refresh cycles, and biologically manufactured consumables reduce both operational and capital expenditures (CapEx) over time. Biomemory has developed a roadmap towards a very low operational cost (OpEx) with low-cost consumables and high-level of automation, along with affordable CapEx compatible enterprise budget, and cloud-providers profitability.
DNA Data Storage is optimized for high-value, long-term, cold data. Typical use cases include protection, regulated datasets, AI training data sets, compliance records, and critical backups requiring durability and integrity over decades.
Data storage is the primary application target of Biomemory, but cybersecurity augmentation is also strong a focus. As the technology matures, molecular systems will also offer unique properties for parallelism and programmability. Over time, this opens pathways toward molecular-scale search and compute capabilities, extending performance beyond traditional microelectronic architectures.
DNA Shield opens our Early Access Program, in the fourth quarter of 2026.